Benzinga's Top Downgrades

Analysts at Bank of America downgraded Questcor Pharmaceuticals

from “buy” to “neutral.” The target price for Questcor Pharmaceuticals has been raised from $46 to $51. Questcor's shares closed at $45.79 yesterday. Analysts at JP Morgan downgraded Idenix Pharmaceuticals

from “overweight” to “neutral.” The target price for Idenix Pharmaceuticals has been lowered from $13 to $5. Idenix's shares closed at $5.13 yesterday. Morgan Stanley downgraded Zynga

from “equal-weight” to “underweight.” Zynga's shares closed at $2.86 yesterday. Analysts at Goldman Sachs downgraded Allergan

from “buy” to “neutral.” The target price for Allergan is set to $110. Allergan's shares closed at $96.24 yesterday.